MYO News & Events

"We expect full year 2025 revenue within our previous guidance range of $40 million to $42 million, which represents an increase of more than 23% versus 2024," said CEO Paul Gudonis.

Reports Q3 revenue $10.09M, consensus $9.44M. "Third quarter revenues were at the high end of our expectations, with International and U.S. orthotics and prosthetics revenues at record levels. Revenue increased while operating expenses decreased on a sequential basis, reflecting our focus on improving operating leverage. We also achieved our strongest quarter of the year for authorizations and orders, while the marketing changes we implemented during the quarter contributed to a sequential decline in cost per pipeline add of 5%. We believe the key to lowering cost per pipeline add is strengthening relationships with the therapists and physicians that are integrated into the continuum of care our patients receive, while reducing our reliance on advertising for lead generation. Under this new program, called MyoConnect, which is expected to generate recurring patient referrals, our clinical team engages with therapists and physicians nationwide to expand the network of healthcare professionals who understand the benefits of the MyoPro. We view MyoConnect as a more scalable means of growing our patient pipeline, while reducing cost per pipeline add and improving pipeline quality, and we are encouraged by the early results. We are also seeing growth from the O&P channel as more clinicians add the MyoPro to their product offerings and begin building their own patient pipeline," said Paul Gudonis, Myomo's Chairman and Chief Executive Officer.

Reports Q2 revenue $9.7M, consensus $9.2M. The Company believes its cash, cash equivalents and short-term investments are sufficient to fund its operations for the next 12 months. "Second quarter revenues exceeded our expectations with 28% growth as we further strengthened our ability to convert current quarter authorizations and orders into revenue. However, several forward-looking operating metrics were not as strong as we anticipated due to factors affecting lead quality and pipeline conversion," said Paul R. Gudonis, CEO. "We are taking decisive action to improve lead quality and pipeline conversion, positioning us for stronger operating performance. Specifically, we are shifting our advertising focus from digital advertising toward television, which in recent experience generated higher quality leads with stronger patient engagement. We are also using our clinical team to engage with therapists and physicians nationwide to expand the number of healthcare professionals that understand the benefits of the MyoPro in improving patient outcomes. By enhancing our eco-system of knowledgeable providers and moving forward in the patients' continuum of care, we expect to secure additional patient referrals for us and our O&P partners."